Photo Courtesy: Allogene Therapeutics Metastatic renal cell carcinoma (RCC) is an advanced kidney cancer with limited treatment options and a five‑year survival rate below 17%. With CIRM’s support, Allogene Therapeutics is developing ALLO‑316, an allogeneic CAR‑T cell therapy that targets CD70, a protein highly expressed on clear cell renal cell carcinoma (ccRCC) tumors. The approach … Continue reading A Step Forward in the Fight Against Advanced Kidney Cancer
Kidney Cancer
Supporting a CAR-T cell trial for kidney cancer
Photo Credit: Allogene Therapeutics. Image of the ALLO-316 allogeneic CAR-T cell therapy. The California Institute for Regenerative Medicine (CIRM) awarded $15 million to Dr. John Le Gall and his team at Allogene Therapeutics. This funding will support the development of ALLO-316, an innovative anti-CD70 CAR-T cell product designed to treat metastatic clear cell renal cell … Continue reading Supporting a CAR-T cell trial for kidney cancer